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Neurodevelopment of HIV-exposed uninfected children in 
South Africa: outcomes from an observational birth cohort 
study
Catherine J Wedderburn, Shunmay Yeung, Andrea M Rehman, Jacob A M Stadler, Raymond T Nhapi, Whitney Barnett, Landon Myer, 
Diana M Gibb, Heather J Zar, Dan J Stein, Kirsten A Donald
Summary
Background HIV infection is known to cause developmental delay, but the effects of HIV exposure without infection 
during pregnancy on child development are unclear. We compared the neurodevelopmental outcomes of HIV-exposed 
uninfected and HIV-unexposed children during their first 2 years of life.
Methods Pregnant women (>18 years of age) at 20–28 weeks’ gestation were enrolled into the Drakenstein Child Health 
cohort study while attending routine antenatal appointments at one of two peri-urban community-based clinics in 
Paarl, South Africa. Livebirths born to enrolled women during follow-up were included in the birth cohort. Mothers 
and infants received antenatal and postnatal HIV testing and antiretroviral therapy per local guidelines. Developmental 
assessments on the Bayley Scales of Infant and Toddler Development, third edition (BSID-III), were done in a subgroup 
of infants at 6 months of age, and in the full cohort at 24 months of age, with assessors masked to HIV exposure status. 
Mean raw scores and the proportions of children categorised as having a delay (scores <–2 SDs from the reference 
mean) on BSID-III were compared between HIV-exposed uninfected and HIV-unexposed children.
Findings 1225 women were enrolled between March 5, 2012, and March 31, 2015. Of 1143 livebirths, 
1065 (93%) children were in follow-up at 6 months and 1000 (87%) at 24 months. Two children were diagnosed 
with HIV infection between birth and 24-month follow-up and were excluded from the analysis. BSID-III 
assessments were done in 260 (24%) randomly selected children (61 HIV-exposed uninfected, 199 HIV-unexposed) 
at 6 months and in 732 (73%) children (168 HIV-exposed uninfected, 564 HIV-unexposed) at 24 months. All 
HIV-exposed uninfected children were exposed to antiretrovirals (88% to maternal triple antiretroviral therapy). 
BSID-III outcomes did not significantly differ between HIV-exposed uninfected and HIV-unexposed children at 
6 months. At 24 months, HIV-exposed uninfected children scored lower than HIV-unexposed for receptive 
language (adjusted mean difference –1·03 [95% CI –1·69 to –0·37]) and expressive language (–1·17 [–2·09 to –0·24]), 
whereas adjusted differences in cognitive (–0·45 [–1·32 to 0·43]), fine motor (0·09 [–0·49 to 0·66]), and gross 
motor (–0·41 [–1·09 to 0·27]) domain scores between groups were not significant. Correspondingly, the proportions 
of HIV-exposed uninfected children with developmental delay were higher than those of HIV-unexposed children 
for receptive language (adjusted odds ratio 1·96 [95% CI 1·09 to 3·52]) and expressive language (2·14 [1·11 to 4·15]).
Interpretation Uninfected children exposed to maternal HIV infection and antiretroviral therapy have increased 
odds of receptive and expressive language delays at 2 years of age. Further long-term work is needed to understand 
developmental outcomes of HIV-exposed uninfected children, especially in regions such as sub-Saharan Africa 
that have a high prevalence of HIV exposure among children.
Funding Bill & Melinda Gates Foundation, SA Medical Research Council, Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
More than 1·4 million children are born to HIV-infected 
mothers annually, and 90% live in sub-Saharan Africa.1 
However, following the success of programmes for the 
prevention of mother-to-child transmission of HIV through 
maternal antiretroviral therapy (ART), most children born 
to HIV-infected mothers are not infected with HIV, and 
there are an estimated 14·8 million HIV-exposed uninfected 
children worldwide.1 Whereas paediatric HIV infection is 
known to delay neurodevelopment,2 the outcomes of 
HIV-exposed uninfected children are less clear.
HIV-exposed uninfected children have increased 
morbidity and mortality,3 and might also have adverse 
developmental outcomes compared with HIV-unexposed 
children. Several studies have described varying degrees 
of impaired cognitive, language, and motor development 
in HIV-exposed uninfected children, particularly in low-
resource settings,4–6 including South Africa.7 However, 
other studies have found no substantial evidence of 
developmental delay.8,9 Few studies have investigated 
children exposed to current first-line antiretroviral drug 
therapy in sub-Saharan Africa, and most have not 
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documented infant feeding mode, which has been 
associated with neurodevelopment.7 Additionally, many 
previous studies have had small sample sizes or cross-
sectional design, or have lacked adequate HIV-unexposed 
comparison groups or assessment of potential con-
founders. Given the heterogeneity of studies to date, 
uncertainty remains regarding the developmental 
outcomes of HIV-exposed uninfected children.
Neurodevelopment during fetal and early life, a time 
of intense brain maturation, forms the basis of academic 
achievement and economic productivity. Identifying the 
children most susceptible to delays in neurodevelopment 
is necessary to focus interventions and improve child 
health outcomes. According to proxy measures of 
stunting and poverty, sub-Saharan Africa has the highest 
proportion of children at risk of not reaching their 
developmental potential worldwide.10 Therefore, under-
standing whether neurodevelopment is impaired in the 
expanding population of HIV-exposed uninfected 
children in this region is important, and studies are 
needed to ascertain the exact nature of any 
developmental delay with appropriate controls in the 
current ART era.3
We aimed to compare neurodevelopmental outcomes 
of HIV-exposed uninfected and HIV-unexposed children 
from the South African Drakenstein Child Health Study 
(DCHS) during their first 2 years of life.
Methods
Study design and participants
The DCHS is a population-based birth cohort study based 
in Paarl (a peri-urban area of the Western Cape, 
South Africa), investigating the early-life determinants of 
child health and development.11,12 The antenatal HIV 
prevalence in this study population is 21%. Pregnant 
women who were older than 18 years of age, receiving 
antenatal care at a participating site, and intending to 
reside in the area for at least a year were enrolled into the 
study at 20–28 weeks’ gestation while attending routine 
antenatal appointments.11,12 Participants were recruited 
from two community-based clinics: T C Newman clinic 
(serving a mixed-ancestry community who speak 
Research in context
Evidence before this study
We searched six external databases (MEDLINE, PubMed, 
Embase, PsychINFO, Africa-Wide Information, and Global 
Health) for articles published from database inception until 
April 30, 2019, that examined the neurodevelopment of 
HIV-exposed uninfected children. The search terms used 
included those related to the concepts of “child”, 
“neurodevelopment”, and “HIV / antiretroviral (ARV) drugs”, 
which were adapted for use with the different databases and 
combined with database-specific filters where available. 
We excluded studies published before the year 2000. 
Longitudinal studies from high HIV-burden countries in the 
current era of antiretroviral therapy (ART) are scarce, as 
highlighted by reviews. Many previous studies have had small 
sample sizes and lacked adequate comparison groups or 
assessment of potential confounders. Overall, there is growing 
recognition that HIV-exposed uninfected children might have 
poorer developmental outcomes compared with 
HIV-unexposed children, particularly in low-income and 
middle-income countries. Several studies have reported 
impairments in cognitive, language, or motor function. 
Other studies, including one from Uganda and Malawi, did not 
find substantial differences between HIV-exposed uninfected 
and HIV-unexposed children. Given that most studies have 
been cross-sectional and that not all data are consistent, the 
exact nature of developmental delay and the clinical relevance 
remain unclear.
Added value of this study
This population-based study investigates the effect of HIV and 
antiretroviral exposure on early child development in a well 
characterised South African cohort in the current ART era. 
We found no difference between HIV-exposed uninfected 
and HIV-unexposed children from the same environment at 
6 months in any developmental domain in our cohort. 
However, by 24 months, HIV-exposed uninfected children had 
significantly poorer receptive and expressive language 
outcomes and had increased risks of delay (scores <–2 SD from 
the reference mean of Bayley Scales of Infant and Toddler 
Development, third edition) in these domains compared with 
HIV-unexposed children after controlling for relevant 
confounders. Additionally, in an exploratory analysis, we found 
an association between language delay and maternal 
immunosuppression. Cognitive and motor outcomes at 
24 months were not significantly affected by HIV exposure.
Implications of all the available evidence
HIV-exposed uninfected children might be at higher risk 
of delayed language development (both receptive and 
expressive) compared with HIV-unexposed children, and these 
delays are identifiable as early as 24 months of age. 
Consistently, previous studies from both high-resource and 
low-resource settings have suggested an association between 
HIV exposure without infection and adverse language 
outcomes. The increased severe language delay is concerning, 
and further follow-up of these children is needed to ascertain 
whether the effects have a continued impact later in life and to 
delineate the potential mechanisms. Identifying those children 
who are most susceptible to poor developmental outcomes is 
necessary to focus interventions and improve child health 
outcomes. Given that almost a quarter of South African 
children are exposed to HIV, and that numbers of HIV-exposed 
uninfected children are increasing globally, these findings 
could have important implications for public health policies.
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Afrikaans) and Mbekweni clinic (serving a predominantly 
black African community who speak isiXhosa), both of 
which provide free maternal and child care. Written 
informed consent was obtained annually for mother–
child pairs. A subgroup of randomly selected children 
underwent developmental assessment at 6 months, and 
all available children were assessed at age 24 months.
This study was approved by the human research ethics 
committee of the Faculty of Health Sciences, University 
of Cape Town (approval numbers 401/2009 and 044/2017), 
and by the London School of Hygiene & Tropical 
Medicine observational and interventions research ethics 
committee (approval number 11903).
Procedures
Maternal HIV status during pregnancy was confirmed by 
routine HIV testing at booking, with retesting of HIV-
negative mothers every 12 weeks, in accordance with 
Western Cape prevention of mother-to-child transmission 
of HIV guidelines. Additionally, maternal interviews and 
HIV status reviews of mothers and children were done by 
study staff at the child’s birth, age 6 weeks, and every 
6 months thereafter. All HIV-infected mothers were 
initiated on antiretroviral drugs according to prevention 
of mother-to-child trans mission guidelines at the time: 
three-drug ART (the first-line ART regimen consisted of 
two nucleoside reverse transcriptase inhibitors plus a 
non-nucleoside reverse transcriptase inhibitor, commonly 
tenofovir plus emtricitabine plus efavirenz) or zidovudine 
from 14 weeks’ gestation, depending on maternal clinical 
and immunological status (before May, 2013); or ART for 
life for all pregnant women (from May, 2013). All 
HIV-exposed uninfected children received prophylaxis 
(nevirapine alone or combined with zidovudine) from 
birth. HIV and ART data were collected by triangulating 
clinic and hospital folder information and maternal self-
report interviews. Maternal CD4 cell count and viral load 
data were obtained from the online National Health 
Laboratory Service system. Where there were multiple 
results, the highest viral load during pregnancy was 
taken, and the lowest CD4 cell count within 1 year before 
childbirth and 3 months post-birth was used to maximise 
numbers. All HIV-exposed children received HIV testing 
as per local guidelines. HIV detection was done by PCR at 
age 6 weeks, and by rapid antibody, PCR, or ELISA at age 
9 months and 18 months. HIV-exposed uninfected 
children were confirmed to have a negative HIV test 
result at age 18 months or a negative test after cessation of 
breastfeeding if this occurred at more than 18 months of 
age. HIV-unexposed children were defined as children 
born to mothers without HIV infection. 
Sociodemographic data were collected between 
weeks 28 and 32 of gestation by trained study staff using 
structured interviews and questionnaires adapted from 
the South African Stress and Health study.11,12
Detailed birth data were obtained at delivery. 
Gestational age was calculated using the best estimated 
delivery date based on antenatal ultrasound, the last 
menstrual period, or the symphysis-fundal height. 
Prematurity was defined as birth at less than 37 weeks’ 
gestation. Infant feeding method and exclusive 
breastfeeding duration were documented by maternal 
report at age 6–14 weeks, 6 months, and 9 months.
Maternal psychosocial data were collected antenatally 
between weeks 28 and 32 of gestation.12 Maternal alcohol 
use during pregnancy was assessed using the Alcohol, 
Smoking, and Substance Involvement Screening Test.12 
Material tobacco exposure during pregnancy was 
assessed by use of the IMMULITE 1000 nicotine 
metabolite kit (Siemens Medical Solutions Diagnostics, 
Glyn Rhonwy, UK) to measure antenatal urine cotinine 
concentration. Maternal depression was assessed with 
the Edinburgh Postnatal Depression Scale (with a score 
of ≥13 considered to indicate depression).12
Developmental assessment
Neurodevelopment was measured with the Bayley Scales 
of Infant and Toddler Development, third edition 
(BSID-III),13,14 which is widely used internationally and 
has been validated in South Africa with reported values 
similar to those of the BSID-III US-based reference 
population.15,16 The objectively measured assessment 
consists of five subscales: cognition, receptive language, 
expressive language, fine motor, and gross motor. 
Trained assessors masked to HIV exposure status 
alternated testing between clinics, assessing equal 
numbers of children at each site and offering language 
prompts in the child’s preferred language. Any child with 
significant developmental delay was referred to the 
relevant health-care service. Inter-assessor reliability was 
assured through training and supervision. Assessors 
were monitored by a paediatric neurodevelopmental 
specialist throughout, who periodically observed 
assessments to ensure standardised data collection 
across sites, accuracy, and continued agreement between 
assessors. A second level of external quality control was 
done centrally before data capture. Scores were entered 
into a specialised BSID-III software programme.
260 children were randomly selected from the original 
cohort as a sampling frame for developmental assessment 
at 6 months of age. If a mother–child pair was unavailable, 
another child aged 6 months was invited to attend from 
those with study follow-up visits that week, based on child 
age at the time (a convenience sample). All available 
children were assessed at age 24 months. Mothers who 
were unavailable at initial contact were tried again up to 
three times, and children who were unwell on the day of 
assessment were rebooked where possible. Raw scores, 
scaled scores, and developmental delay are reported. Raw 
scores represent the sum of individual items the child 
passes on each subscale. Raw scores were converted to 
age-adjusted scaled scores standardised using normative 
data derived from a US reference population, with a range 
of 1–19 and mean of 10 (SD 3), with correction for 
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prematurity at 6 months.13 A BSID-III score of less than 
–2 SDs from the BSID-III reference mean was used to 
define a clinically significant delay in any domain.7,13
Statistical analysis
Maternal and child sociodemographic characteristics were 
expressed as mean (SD) for continuous data or absolute 
frequencies (%) for categorical data, and were compared 
between HIV-exposed uninfected and HIV-unexposed 
children with BSID-III results at 6 months and 24 months 
using descriptive statistics (t tests or χ² tests).
The associations between HIV exposure and each 
BSID-III subscale (cognitive, receptive language, 
expressive language, fine motor, and gross motor) at 
6 months and 24 months of age were compared with use 
of linear regression models for raw scores and logistic 
regression models for developmental delay. Standardised 
effect sizes were reported as Cohen’s d values. A directed 
acyclic graph (DAG) was constructed using DAGitty, 
according to previously published literature, to delineate 
assumptions regarding the causal pathway between HIV 
exposure and neurodevelopment. Multivariable models 
were then created using all potential confounders of the 
exposure–outcome relationship, as determined a priori 
by the DAG (house hold income, maternal education, 
maternal age, and sex and age of child). Residuals were 
checked for normality through quantile-quantile plots to 
confirm the linearity assumption for the models. 
Adjusted mean differences, adjusted odds ratios (ORs), 
and 95% CIs are presented.
Additional analyses were done by adjusting the models 
for key potential mediating variables identified from the 
DAG (prematurity, maternal depression, and breastfeeding 
[exclusive breastfeeding duration and exclusive breast-
feeding to 6 months]) to assess any changes to specific 
domain associations. Sensitivity analyses were done to 
examine the effect of site and home language in a restricted 
subanalysis of Mbekweni clinic, where the majority of 
HIV-exposed uninfected children reside. A separate 
analysis limited to HIV-exposed uninfected children whose 
mothers were on first-line ART was also done. Finally, the 
association between maternal CD4 cell count 
(dichotomised into ≤500 and >500 cells per μL, as per 
previous guidelines,17 with similar group sizes) and 
developmental outcomes was explored in BSID-III 
language subscales to provide direction for future work.
Statistical analyses were done with STATA software 
(version 14.0). P values of less than 0·05 (two-tailed) were 
considered to indicate statistical significance.
Role of the funding source
The funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results 
Between March 5, 2012, and March 31, 2015, 1225 pregnant 
women were enrolled into the study. Of 1143 live infants 
born to 1137 enrolled women, follow-up was available 
for 1065 (93%) children at 6 months and 1000 (87%) 
at 24 months of age, excluding two children with 
HIV infection identified between birth and 24-month 
follow-up (figure 1). BSID-III assessments were done 
for a subgroup of 260 (24%) uninfected children 
(61 HIV-exposed uninfected and 199 HIV-unexposed) at 
6 months and for 732 (73%) children (168 HIV-exposed 
uninfected and 564 HIV-unexposed) at 24 months. 
Demographic characteristics of HIV-exposed uninfected 
and HIV-unexposed children at 6 months and 24 months 
were similar (table 1). Mothers with and mothers without 
HIV infection did not differ significantly in terms of 
household income, employment status, marital status, 
maternal depression, or alcohol use during pregnancy. 
Similar proportions of HIV-exposed uninfected and 
For more on DAGitty 
see http://dagitty.net/
Figure 1: Drakenstein Child Health Study profile
BSID-III=Bayley Scales of Infant and Toddler Development, third edition. *Excluded 
from this analysis, but not from the Drankenstein Child Health Study follow-up. 
†209 (80%) of the 260 children assessed on BSID-III at 6 months were also 
assessed at 24 months (46 HIV-exposed uninfected and 163 HIV-unexposed). 
‡No show because of violence, poor weather conditions, or seasonal work.
1225 pregnant women enrolled
680 at Mbekweni clinic
545 at T C Newman clinic
88 women excluded
66 lost to follow-up
22 miscarriage or stillbirth
78 children excluded
76 lost to follow-up
2 HIV-infected*
1143 livebirths (from 1137 women) included in cohort
248 HIV-exposed uninfected
895 HIV-unexposed
65 lost to follow-up
1065 children at 6-month follow-up
260 assessed on BSID-III
61 HIV-exposed uninfected
199 HIV-unexposed
805 not assessed on BSID-III
1000 at 24-month follow-up
732 assessed on BSID-III†
168 HIV-exposed uninfected
564 HIV-unexposed 
268 not assessed on BSID-III
105 not in area at 24 months
116 mothers uncontactable or did not attend‡
16 mothers unable to attend bacause of work
7 children unwell and unable to attend at 24 months
24 other reasons
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6 months 24 months
HIV-exposed (N=61) HIV-unexposed (N=199) p value HIV-exposed (N=168) HIV-unexposed (N=564) p value
Child age at BSID-III assessment, days 184 (11) 184 (12) 0·84 732 (16) 733 (16) 0·53
Sex ·· ·· 0·70 ·· ·· 0·20
Male 33/61 (54%) 102/199 (51%) ·· 94/168 (56%) 284/564 (50%) ··
Female 28/61 (46%) 97/199 (49%) ·· 74/168 (44%) 280/564 (50%) ··
Site (proxy for primary language) ·· ·· <0·0001 ·· ·· <0·0001
T C Newman clinic (Afrikaans) 3/61 (5%) 130/199 (65%) 13/168 (8%) 331/564 (59%) ··
Mbekweni clinic (isiXhosa) 58/61 (95%) 69/199 (35%) 155/168 (92%) 233/564 (41%) ··
Monthly household income, South African 
rand*
·· ·· 0·74 ·· ·· 0·93
<1000 26/61 (43%) 88/199 (44%) ·· 66/168 (39%) 221/564 (39%) ··
1000–5000 30/61 (49%) 89/199 (45%) ·· 83/168 (49%) 273/564 (48%) ··
>5000 5/61 (8%) 22/199 (11%) ·· 19/168 (11%) 70/564 (12%) ··
Maternal education ·· ·· 0·99 ·· ·· 0·0010
Any primary 4/61 (7%) 11/199 (6%) ·· 19/168 (11%) 40/564 (7%) ··
Any secondary 34/61 (56%) 115/199 (58%) ·· 108/168 (64%) 290/564 (51%) ··
Completed secondary 20/61 (33%) 64/199 (32%) ·· 37/168 (22%) 196/564 (35%) ··
Any tertiary 3/61 (5%) 9/199 (5%) ·· 4/168 (2%) 38/564 (7%) ··
Maternal death 0 0 ·· 2/168 (1%) 1/564 (0·2%) 0·071
Mother attended BSID-III assessment 54/60 (90%) 179/198 (90%) 0·93 143/168 (85%) 470/549 (86%) 0·87
Mother in employment 15/61 (25%) 43/199 (22%) 0·63 41/168 (24%) 142/564 (25%) 0·84
Mother married or cohabitating 24/61 (39%) 71/198 (36%) 0·62 75/168 (45%) 217/563 (39%) 0·16
Maternal age at birth, years 29·8 (5·4) 25·5 (5·3) <0·0001 30·4 (5·3) 26·3 (5·6) <0·0001
Gestational age at delivery, weeks 38·8 (2·3) 38·7 (2·2) 0·80 38·5 (2·6) 38·6 (2·5), N=562 0·64
Premature birth (<37 weeks’ gestation) 9/61 (15%) 24//199 (12%) 0·58 23/168 (14%) 81/562 (14%) 0·81
Birthweight
Mean (SD), g 3102 (501) 3043 (552) 0·46 3022 (583) 3039 (579) 0·74
Low birthweight (<2·5 kg) 7/61 (11%) 25/199 (13%) 0·82 23/168 (14%) 84/564 (15%) 0·70
Birth length, cm 49·5 (4·3) 49·8 (3·7), N=198 0·60 49·9 (4·1), N=165 49·9 (3·6), N=555 0·94
Birth head circumference, cm 33·5 (1·8) 33·5 (1·9), N=198 0·88 33·6 (2·1), N=167 33·5 (2·1), N=558 0·72
WHO length/height-for-age Z-score –0·44 (1·5), N=59 –0·44 (1·7), N=189 0·98 –1·17 (1·2), N=130 –1·09 (1·2), N=449 0·49
Maternal smoking during pregnancy (urine 
cotinine concentration)†
·· ·· 0·010 ·· ·· 0·10
Active (≥500 ng/mL) 14/61 (23%) 87/195 (45%) ·· 46/164 (28%) 204/550 (37%) ··
Passive (10–500 ng/mL) 31/61 (51%) 71/195 (36%) ·· 79/164 (48%) 229/550 (42%) ··
Non-smoker (<10 ng/mL) 16/61 (26%) 37/195 (19%) ·· 39/164 (24%) 117/550 (21%) ··
Moderate-to-severe maternal alcohol use 
during pregnancy
8/55 (15%) 44/192 (23%) 0·18 16/148 (11%) 79/507 (16%) 0·15
Maternal depression during pregnancy 9/55 (16%) 57/191 (30%) 0·047 33/149 (22%) 123/508 (24%) 0·60
Exclusive breastfeeding duration, months
Mean (SD) 1·1 (2·0) 2·4 (2·0) <0·0001 1·5 (2·1) 2·3 (1·9), N=563 <0·0001
6 months‡ 7/61 (11%) 37/199 (19%) 0·20 24/168 (14%) 100/563 (18%) 0·29
Maternal HIV diagnosis timepoint
Before pregnancy 44/59 (75%) ·· ·· 122/163 (75%) ·· ··
During pregnancy 15/59 (25%) ·· ·· 41/163 (25%) ·· ··
Maternal CD4 cell count in pregnancy, cells/μL
Median (range) 522 (298–691), N=56 ·· ·· 441 (294–618), N=151 ·· ··
<200 6/56 (11%) ·· ·· 17/151 (11%) ·· ··
200–350 12/56 (21%) ·· ·· 37/151 (25%) ·· ··
350–500 9/56 (16%) ·· ·· 33/151 (22%) ·· ··
>500 29/56 (52%) ·· ·· 64/151 (42%) ·· ··
(Table 1 continues on next page)
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6 months 24 months
HIV-exposed (N=61) HIV-unexposed (N=199) p value HIV-exposed  (N=168) HIV-unexposed  (N=564) p value
(Continued from previous page)
Highest maternal viral load during pregnancy
Below detectable limit (<40 copies/mL) 25/36 (69%) ·· ·· 69/108 (64%) ·· ··
Detectable (≥40–1000 copies/mL) 6/36 (17%) ·· ·· 25/108 (23%) ·· ··
Unsuppressed (>1000 copies/mL) 5/36 (14%) ·· ·· 14/108 (13%) ·· ··
Antiretroviral drug initiation
Before pregnancy 22/59 (37%) ·· ·· 71/165 (43%) ·· ··
During pregnancy 37/59 (63%) ·· ·· 94/165 (57%) ·· ··
Antiretroviral regimen during pregnancy
Prevention of mother-to-child 
transmission prophylaxis (zidovudine)
9/58 (16%) ·· ·· 20/163 (12%) ·· ··
First-line triple therapy§ 48/58 (83%) ·· ·· 132/163 (81%) ·· ··
Second-line or third-line therapy 1/58 (2%) ·· ·· 11/163 (7%) ·· ··
Infant prophylaxis
Nevirapine alone 55/60 (92%) ·· ·· 145/167 (87%) ·· ··
Nevirapine and zidovudine 5/60 (8%) ·· ·· 22/167 (13%) ·· ··
Data are n/N (%), mean (SD), or median (IQR). Continuous variables were compared with unpaired t tests; categorical variables were compared with χ² tests. All percentages calculated on non-missing values. 
N values are indicated where the number of participants with available data differs from the total group size. Missing data: birth head circumference (n=1 at 6 months, n=7 at 24 months); birth length (n=1 at 
6 months, n=12 at 24 months); birthweight (n=1 at 24 months); WHO length/height-for-age Z score (n=12 at 6 months, n=153 at 24 months); gestation delivery (n=2 at 24 months); breastfeeding duration 
(n=1 at 24 months). Maternal CD4 taken as the lowest CD4 from 1 year before to 3 months after delivery to reflect maternal immunosuppression during pregnancy with the highest sample size. BSID-III=Bayley 
Scales of Infant and Toddler Development, third edition. *1000 South African rand is approximately equal to US$75. †p=0·22 (6 months) and p=0·50 (24 months) for non-smoking versus active and passive 
smoking together. ‡Exclusive breastfeeding to 6 months was defined as exclusive breastfeeding for >5 months of age. §A non-nucleoside reverse-transcriptase inhibitor backbone and two nucleoside reverse 
transcriptase inhibitors, most commonly efavirenz with tenofovir and emtricitabine as a fixed-dose combination, although some mothers received nevirapine-based treatment; of those mothers on first-line 
triple antiretroviral therapy, 42 (88%) at 6 months and 116 (88%) at 24 months received efavirenz-based therapy.  No mothers in the HIV-unexposed group were taking any antiretrovirals during pregnancy. 
Table 1: Demographic characteristics of children assessed on BSID-III at 6 months and 24 months according to HIV exposure
HIV-exposed HIV-unexposed Unadjusted Adjusted*
N Mean raw score 
(SD)
N Mean raw score 
(SD)
Mean difference 
(95% CI)
p value Effect size, 
Cohen’s d 
(95% CI)
Mean difference 
(95% CI)
p value Effect size, 
Cohen’s d 
(95% CI)
6 months
Cognitive 60 27·55 (2·82) 196 27·08 (3·69) 0·47 
(–0·55 to 1·49)
0·37 0·13 
(–0·16 to 0·42)
0·69 
(–0·33 to 1·72)
0·19 0·20 
(–0·09 to 0·49)
Receptive 
language
60 9·78 (1·55) 194 9·57 (1·65) 0·22 
(–0·26 to 0·69)
0·37 0·13 
(–0·16 to 0·42)
0·23 
(–0·28 to 0·73)
0·38 0·14 
(–0·15 to 0·43)
Expressive 
language
61 8·62 (2·72) 194 8·89 (2·61) –0·26 
(–1·03 to 0·50)
0·50 –0·10 
(–0·39 to 0·19)
–0·42 
(–1·22 to 0·39)
0·31 –0·16 
(–0·45 to 0·13)
Fine motor 61 21·79 (2·85) 196 21·60 (3·03) 0·19 
(–0·67 to 1·05)
0·67 0·06 
(–0·22 to 0·35)
0·55 
(–0·32 to 1·42)
0·22 0·19 
(–0·10 to 0·47)
Gross motor 61 24·75 (3·73) 195 24·54 (3·66) 0·21 
(–0·85 to 1·27)
0·70 0·06 
(–0·23 to 0·34)
0·57 
(–0·48 to 1·62)
0·29 0·16 
(–0·13 to 0·44)
24 months
Cognitive 167 54·84 (5·06) 562 55·69 (4·73) –0·85 
(–1·68 to –0·02)
0·045 –0·18 
(–0·35 to –0·003)
–0·45 
(–1·32 to 0·43)
0·32 –0·09 
(–0·27 to 0·08)
Receptive 
language
165 19·83 (3·54) 556 21·10 (3·72) –1·27 
(–1·91 to –0·63)
0·0001 –0·34 
(–0·51 to –0·16)
–1·03 
(–1·69 to –0·37)
0·0024 –0·28 
(–0·45 to –0·10)
Expressive 
language
158 22·91 (5·37) 542 24·45 (4·94) –1·54 
(–2·43 to –0·64)
0·0008 –0·30 
(–0·48 to –0·12)
–1·17 
(–2·09 to –0·24)
0·013 –0·23 
(–0·41 to –0·05)
Fine motor 166 37·40 (3·34) 562 37·51 (3·10) –0·13 
(–0·68 to 0·42)
0·64 –0·04 
(–0·21 to 0·13)
0·09 
(–0·49 to 0·66)
0·77 0·03 
(–0·15 to 0·20)
Gross motor 159 53·07 (3·37) 535 53·31 (3·66) –0·24 
(–0·88 to 0·39)
0·46 –0·07 
(–0·24 to 0·11)
–0·41 
(–1·09 to 0·27)
0·24 –0·11 
(–0·29 to 0·06)
Residuals were assessed for each model using quantile–quantile plots and were normally distributed. Negative mean difference estimates indicate that HIV exposure was associated with lower total raw scores in 
that BSID-III domain (ie, poorer outcomes). BSID-III=Bayley Scales of Infant and Toddler Development, third edition. *Adjusted for child age, child sex, maternal education, household income, and maternal age.
Table 2: Unadjusted and adjusted mean differences in BSID-III domain raw scores at 6 months and 24 months according to HIV exposure
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HIV-unexposed children were born premature or with 
low birthweight. Most children attended the BSID-III 
assessment with their mother. Exclusive breastfeeding 
was uncommon, with less than 20% of mothers 
exclusively breastfeeding for 6 months. Among children 
who exclusively breastfed, breast feeding duration 
was shorter for HIV-exposed uninfected than for 
HIV-unexposed children. Overall, a higher proportion of 
children seen at the Mbekweni clinic were HIV-exposed 
uninfected than were children seen at the T C Newman 
clinic. HIV-infected mothers were on average older at the 
time of childbirth than were uninfected mothers.
Among children assessed at 24 months, HIV-infected 
mothers had lower educational attainment than did 
uninfected mothers. Median maternal CD4 was 441 cells 
per μL, and 69 (64%) of those with available results had 
an undetectable viral load. Maternal antiretroviral drug 
regimens included zidovudine prophylaxis for preven-
tion of mother-to-child transmission (12%), first-line 
three-drug ART (81%), and second-line or third-line 
protease inhibitor-containing therapies (7%; appendix 
p  1). 43% of women initiated antiretrovirals before 
pregnancy, and 88% of mothers on first-line ART had 
efavirenz-based therapy. Children received post-exposure 
prophylaxis with nevirapine alone (87%), or nevirapine 
and zidovudine (13%).
The children with BSID-III outcomes were largely 
representative of the full cohort at each timepoint 
(appendix p 2), although at 24 months they had a higher 
maternal age, a higher proportion of maternal alcohol 
use, and a lower proportion of premature birth. The 
highest percentage of missing data in any single BSID-III 
domain was 5%.
At 6-month BSID-III assessments, HIV-exposed 
uninfected and HIV-unexposed children showed no 
significant differences in mean raw scores on any of the 
subscales (table 2). Mean scaled scores for all subscales 
were within 1 SD of the BSID-III reference mean (mean 
score 10 [SD 3]; appendix p 4). Numbers of children with 
developmental delay were low across the cohort 
(two to seven children in any subscale).
At 24 months, univariate analysis of BSID-III cognition 
outcomes showed that HIV-exposed uninfected children 
had lower mean raw scores than did HIV-unexposed 
children (mean difference –0·85 [95% CI –1·68 to –0·02]). 
However, this difference was attenuated after adjustment 
for confounding variables (–0·45 [–1·32 to 0·43]; table 2). 
The proportions of children with developmental delay 
(defined as a scaled score less than –2 SDs from the BSID-
III reference mean) on the cognition subscale were similar 
between HIV-exposed uninfected and HIV-unexposed 
children (11% vs 9%, adjusted OR 1·01 [95% CI 
0·55 to 1·85]; table 3).
In both unadjusted and adjusted models, HIV exposure 
was associated with lower 24-month scores for receptive 
language (adjusted mean difference –1·03 [–1·69 to –0·37]) 
and expressive language (adjusted mean difference 
–1·17 [–2·09 to –0·24]; table 2). Although the effect sizes 
were small (adjusted Cohen’s d –0·28 [95% CI 
–0·45 to –0·10] for receptive and –0·23 [–0·41 to –0·05] for 
expressive language), these differences represent reduced 
ability to understand the meaning of words and commands 
See Online for appendix
Figure 2: Directed acyclic graph
We constructed a directed acyclic graph using DAGitty to examine for possible confounding in the relationship 
between HIV and ART exposure and child developmental performance on the Bayley Scales of Infant and Toddler 
Development, third edition, at 6 months and 24 months in the Drakenstein Child Health Study, using multiple 
sources.3,10–12 In this model, site acts as a proxy for home language and ethnicity. Maternal psychosocial factors 
include maternal depression, alcohol use, and smoking. Minimal sufficient adjustment sets for estimating the total 
effect of maternal HIV and ART exposure on child neurodevelopment include socioeconomic status (household 
income), maternal education, and maternal age. ART=antiretroviral therapy.
Viral load
Maternal HIV
Socioeconomic status
(household income)
Site
Maternal 
education
Maternal age
Child sex
Child ageChild neurodevelopment
Maternal 
ART
Breastfeeding
Prematurity or
low birthweight
Maternal
psychosocial
factors
CD4
cell 
count
Causal path
Biasing path
Other path
Exposure
Outcome
Ancestor of outcome
Ancestor of exposure
and outcome
Other variable
Infants with delay, n/N (%) Unadjusted Adjusted*
HIV-exposed HIV-unexposed OR (95% CI) p value OR (95% CI) p value
Cognitive 18/167 (11%) 52/562 (9%) 1·18 
(0·67 to 2·09)
0·56 1·01 
(0·55 to 1·85)
0·97
Receptive 
language
23/165 (14%) 40/556 (7%) 2·09 
(1·21 to 3·61)
0·0081 1·96 
(1·09 to 3·52)
0·025
Expressive 
language
18/158 (11%) 31/542 (6%) 2·12 
(1·15 to 3·90)
0·016 2·14 
(1·11 to 4·15)
0·024
Fine motor 6/166 (4%) 12/562 (2%) 1·72 
(0·64 to 4·65)
0·29 1·53 
(0·53 to 4·42)
0·44
Gross motor 6/159 (4%) 19/535 (4%) 1·07 
(0·42 to 2·71)
0·90 1·23 
(0·44 to 3·43)
0·69
We did a complete case analysis by outcome. ORs greater than 1 indicate that HIV exposure was associated with higher 
risk of delay in that BSID-III domain (ie, poorer outcomes). Total number of participants assessed (N) for each domain 
was the same for both unadjusted and adjusted models; no covariates had missing data. BSID-III=Bayley Scales of 
Infant and Toddler Development, third edition. OR=odds ratio. *Adjusted for child age, child sex, maternal education, 
household income, and maternal age.
Table 3: Odds of developmental delay by BSID-III domain at 24 months according to HIV exposure
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in receptive language, and reduced ability to use sounds 
and words to communicate in expressive language. 
Correspondingly, greater proportions of HIV-exposed 
uninfected than HIV-unexposed children had delayed 
development in receptive language (14% vs 7%, adjusted OR 
1·96 [1·09 to 3·52]) and expressive language (11% vs 6%, 
2·14 [1·11 to 4·15]; table 3).
There were no differences in mean raw scores or the 
proportions of children with developmental delays 
between HIV-exposed uninfected and HIV-unexposed 
children with regard to fine motor or gross motor 
domains on 24-month BSID-III assessment (tables 2, 3).
In sensitivity analyses adjusting separately for 
exclusive breastfeeding, premature birth, and maternal 
depression (factors identified to potentially be on the 
causal pathway between HIV exposure and neuro-
development; figure 2, appendix pp 5–7), HIV exposure 
remained associated with lower receptive and expressive 
language raw scores. Two exclusive breast feeding 
classifications were examined (exclusive breastfeeding 
duration and exclusive breastfeeding to 6 months 
[defined as exclusive breastfeeding for >5 months of 
age]) and, in both cases, the exposure–outcome 
relationship remained the same. To address between-
group differences in site and home language, we did a 
restricted analysis of children from Mbekweni clinic 
(appendix p 8). The overall trends in associations were 
similar to those of the full sample, the point estimates 
held, and the proportion of children with delayed 
development in receptive language and expressive 
language remained the same, although precision was 
reduced (which was expected with the smaller sample 
size). Alcohol exposure (appendix p 9) showed no effect 
on the associations between receptive or expressive 
language development and HIV exposure.
In a subgroup analysis comparing only HIV-exposed 
uninfected children whose mothers were initiated on 
first-line triple ART (n=132) with HIV-unexposed 
children, language impairments remained associated 
with HIV exposure (appendix p 10). In an exploratory 
analysis comparing outcomes among children born to 
mothers with and without immuno suppression, a 
maternal CD4 cell count of 500 cells per μL or less was 
associated with lower receptive and expressive language 
scores and increased prevalence of developmental 
delays in these domains versus children born to 
mothers without HIV infection (table 4).
Discussion
The results from this South African birth cohort show that 
HIV-exposed uninfected children had poorer language 
outcomes at 24 months, but not at 6 months, when 
compared with HIV-unexposed children. To our 
knowledge, this is the largest longitudinal study to report 
delayed language development in both receptive and 
expressive domains in HIV-exposed uninfected children in 
South Africa, building on previous literature18–21 suggesting 
that language might be impaired in this population.
Overall, children in this cohort showed increased 
developmental impairment over time. At 6 months, 
developmental performance was no different between 
HIV-exposed uninfected and HIV-unexposed children. 
N Raw scores Delayed development
Mean (SD) Unadjusted Adjusted* Delayed, N 
(%)
Unadjusted Adjusted*
Mean difference 
(95% CI)
p value Mean difference 
(95% CI)
p value OR (95% CI) p value OR (95% CI) p value
Receptive language
HIV-unexposed 556 21·10 (3·72) 0·00 (ref) ·· 0·00 (ref) ·· 40 (7%) 1·00 (ref) ·· 1·00 (ref) ··
Maternal CD4 
count >500 cells 
per μL
62 20·35 (3·24) –0·74 
(–1·71 to 0·22)
0·13 –0·48 
(–1·45 to 0·49)
0·33 7 (11%) 1·64 
(0·70 to 3·84)
0·25 1·56 
(0·65 to 3·73)
0·32
Maternal CD4 
count ≤500 cells 
per μL
86 19·27 (3·70) –1·83 
(–2·67 to –0·99)
<0·0001 –1·54 
(–2·40 to –0·68)
0·0005 14 (16%) 2·51 
(1·30 to 4·84)
0·0061 2·40 
(1·19 to 4·83)
0·014
Expressive language
HIV-unexposed 542 24·45 (4·94) 0·00 (ref) ·· 0·00 (ref) ·· 31 (6%) 1·00 (ref) ·· 1·00 (ref) ··
Maternal CD4 
count >500 cells 
per μL
60 23·87 (5·04) –0·58 
(–1·92 to 0·76)
0·40 –0·16 
(–1·50 to 1·18)
0·82 5 (8%) 1·50 
(0·56 to 4·01)
0·42 1·42 
(0·52 to 3·89)
0·50
Maternal CD4 
count ≤500 cells 
per μL
81 22·09 (5·47) –2·36 
(–3·53 to –1·19)
<0·0001 –1·92 
(–3·12 to –0·72)
0·0018 11 (14%) 2·59 
(1·25 to 5·38)
0·011 2·73 
(1·24 to 6·03)
0·013
ORs greater than 1 indicate higher risk of delay in that BSID-III domain (ie, poorer outcomes) versus the reference group; negative mean difference estimates indicate lower total raw scores in that domain (ie, 
poorer outcomes) versus the reference group. Maternal CD4 taken as the lowest CD4 from 1 year before to 3 months after delivery to reflect maternal immunosuppression during pregnancy with the highest 
sample size. OR=odds ratio. BSID-III=Bayley Scales of Infant and Toddler Development, third edition. *Adjusted for child age, child sex, maternal education, household income, and maternal age.
Table 4: Receptive and expressive language outcomes on BSID-III at 24 months according to maternal CD4 cell counts
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More subtle language impairments might not easily be 
identified at such a young age before explicit verbal 
communication has developed. Alcock and colleagues 
also found worsening language outcomes in older (aged 
16–30 months vs 8–15 months) HIV-exposed uninfected 
children in Kenya.18 In our study, by 24 months of age, 
HIV-exposed uninfected children had language 
impairment in terms of both raw scores and formal delay 
categorisation, suggesting clinically significant impair-
ment. Although the effect sizes were small, these 
findings are concerning in the context of a growing 
HIV-exposed uninfected population in sub-Saharan 
Africa. The associations between exposure to HIV and 
antiretroviral therapy and poorer language outcomes 
remained after examining infant feeding method, 
maternal depression, and prematurity as potential 
mediators. We did not find any associations between 
exposure to HIV and antiretroviral therapy and cognitive 
or motor development, similar to the results of studies 
from Botswana, Uganda, and Malawi.8,9 However, the 
BSID-III might underestimate delay, which could also 
contribute to the lack of differences.16
Previous research has found language to be particularly 
affected in HIV-infected children, and has suggested that 
language development is also possibly affected in HIV-
exposed uninfected children in both high-resource and 
low-resource settings, supporting our results.2,18 A study 
of HIV-exposed uninfected children in the USA found 
increased risk of language impairments compared with 
population norms.19 In the Democratic Republic of the 
Congo, expressive language (and motor) delays were 
found in HIV-uninfected preschool children born to 
mothers with HIV/AIDS.20 A study in Botswana reported 
that HIV-exposed uninfected 2-year olds had increased 
adverse expressive language outcomes,9 and receptive 
language was impaired in HIV-exposed uninfected 
children aged 3 years in Uganda.21 A recent South African 
study of 1-year-old children did not find any language 
delay; however, only expressive language was assessed.7 It 
is possible that early exposures only manifest later and 
that language delay might not be evident as early as 
12 months of age, as observed in the current study.
We assessed language using the BSID-III, which 
measures preverbal communication, vocabulary develop-
ment, and recognition of common objects and animals. 
The tasks assessed in children younger than 24 months 
are more universally applicable than those for older 
children. The BSID-III has been validated in South Africa 
in infancy and found to be a culturally appropriate tool.15,16 
In young children (up to 2 years of age), research has 
shown many similarities in the sequence of language 
acquisition and vocabulary growth across languages and 
communities.22 Despite site differences, the HIV-exposed 
uninfected and HIV-unexposed groups in the current 
study had similar socioeconomic backgrounds, and the 
results of the analysis restricted to children seen at the 
Mbekweni clinic (isiXhosa-speaking) with nearly 
400 children support the main findings (appendix p 8).
The mechanisms for the observed developmental delays 
require further investigation to understand whether a 
particular subgroup of HIV-exposed uninfected children 
might be most susceptible. Our exploratory analyses 
suggest an effect of maternal immunosuppression on 
neurodevelopment, with maternal CD4 cell counts of 
500 cells per μL or fewer associated with poorer language 
outcomes than those of unexposed children. Growing 
evidence indicates that maternal immune activation 
affects neuro development in utero23 and neuro-
inflammation might have an important role in cognitive 
dysfunction.24 Previously reported neuroimaging findings 
from a neonatal subgroup of the DCHS found white 
matter differences between HIV-exposed uninfected and 
HIV-unexposed neonates.25 These CD4 results from our 
study also support findings from a previous study that 
showed that maternal viral load might predict poorer 
developmental outcomes,8 highlighting the importance of 
optimising maternal health for child neurodevelopment.
Multiple socioeconomic, environmental, and biological 
factors influence child neurodevelopment.10 We adjusted 
for potential confounders in our analyses; however, the 
effects of HIV exposure on language development might 
be mediated through other pathways, including parent–
child interaction, that are affected by caregiver physical 
or psychological health, for which further investigation is 
needed to inform interventions. Evidence for other 
possible mechanisms, including antiretroviral neuro-
toxicity, is lacking, and deciphering the role (if any) of 
antiretroviral neurotoxicity from HIV exposure is 
challenging. Antiretrovirals are known to cross the 
placental barrier and have been linked to mitochondrial 
toxicity, preterm birth, and biological deficits.26 In a US 
cohort study, language outcomes were affected by specific 
antiretrovirals (including atazanavir associated with late 
language emergence at 1 year of age and tenofovir with 
speech impairment at 3 years but not 5 years of age).19 In 
Botswana, no effect of monotherapy versus triple ART 
therapy on develop mental outcomes was observed,27 
although efavirenz exposure was associated with lower 
receptive language scores at 2 years of age compared 
with non-efavirenz-containing therapies.28 A study from 
Uganda and Malawi found no increased developmental 
risk associated with maternal ART.8 Our findings were 
confirmed when analyses were restricted to those infants 
whose mothers received first-line ART (the majority of 
whom were receiving efavirenz-based therapy). Careful 
pharmacovigilance is needed going forwards to monitor 
potential antiretroviral neurotoxicity.
The strengths of this prospective study include the 
use of a validated measure of neurodevelopment, as 
well as the large sample size and inclusion of an 
appropriate control group from a similar socioeconomic 
environ ment. Additionally, the cohort recruitment 
spanned from 2012 to 2015, with heterogeneity in ART 
regimens and maternal immune status, although most 
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mothers were on first-line ART, both of which are 
representative of populations across sub-Saharan Africa. 
The cohort had a high prevalence of socio demographic 
risk factors, similar to other low-income and middle-
income settings, giving this study good generalis-
ability.12,14 Finally, the study measured neuro development 
at two timepoints, and follow-up continues for these 
children. Research in high HIV prevalence settings 
using longitudinal data is essential to inform global 
child development research priorities.29
This study has some important limitations. First, the 
sample size at 6 months was small and might have 
been underpowered to detect a difference at this 
timepoint. Second, at 24 months, not all children in the 
cohort received a BSID-III assessment and, although 
we did sensitivity analyses to explore the effect of 
potential bias, the possibility of selection bias remains. 
Third, although the BSID-III is a well recognised tool, 
there are reliability concerns and further standardis-
ation in sub-Saharan African settings is required; for 
example, the categorisation of delay is based on scaled 
scores using normative US data that might not be 
generalisable to a South African population. However, 
we reported raw scores with similar patterns to the 
results based on delay categorisation and compared 
against a control group, adding validity to our outcomes. 
Fourth, participants might have had hearing loss that is 
known to affect language development, and hearing 
assessments are ongoing. Finally, despite similar 
backgrounds, there were some differences between the 
HIV-exposed uninfected and HIV-unexposed groups, 
including lower proportions of breastfed infants among 
HIV-exposed uninfected children. However, the 
prevalence of exclusive breast feeding was low across 
the whole population. The multivariable models 
adjusted for confounders and accounted for potential 
mediating variables, and, by restricting analyses to the 
Mbekweni clinic, we attempted to minimise residual 
confounding.
Elucidating risk factors associated with delayed 
development could inform effective preventive and 
intervention strategies. HIV exposure appears to affect 
emerging language development, which is foundational 
to school readiness and academic outcomes.30 As there 
are an estimated 14·8 million HIV-exposed uninfected 
children worldwide,1 this research could have significant 
public health implications. Furthermore, HIV-exposed 
uninfected children identified with early developmental 
delay might benefit from interventions to improve 
outcomes. Future work is needed to assess if these 
findings are replicated in cohorts with higher breast-
feeding prevalence, and to ascertain their long-term 
significance. Research is also needed to define the causal 
pathways behind adverse outcomes in HIV-exposed 
uninfected children, including the role of maternal 
psychological and family socioeconomic factors, exposure 
to HIV, and the effect of ART regimens and initiation 
timing, to provide future interventions. Neurocognitive 
follow-up and neuroimaging of these children is ongoing 
and could add to our understanding of the mechanisms 
behind the observed developmental delays.14
In conclusion, we found uninfected children exposed to 
maternal HIV and antiretroviral drugs had delayed 
receptive and expressive language development identifiable 
as early as 24 months of age, compared with HIV-unexposed 
children from similar environments. Given that almost a 
quarter of children in South Africa are HIV-exposed and 
numbers are expanding globally, further work is needed to 
understand the long-term developmental outcomes of 
HIV-exposed uninfected children.
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